Primary aldosteronism

Primary aldosteronism (PA) is a common yet underdiagnosed cause of secondary hypertension. This project aims to identify novel therapeutic strategies by combining high-throughput screening with advanced cellular and animal models. Building on prior development of mutation-specific adrenocortical cell lines, we explore compounds that selectively target PA-driving mutations through two complementary approaches: restoring ion channel function and inducing ferroptosis-mediated cell death in affected cells. Promising candidates will be validated using a newly developed zebrafish model and in ex vivo systems from patient tumors. These efforts aim to advance personalized treatments for both familial and acquired forms of PA.